Claims
- 1. A pharmaceutically-acceptable amine salt selected from the group consisting of the pivmecillinam salt of 6.beta.-bromopenicillanic acid; the pivmecillinam salt of 6.beta.-iodopenicillanic acid; the bacmecillinam salt of 6.beta.-bromopenicillanic acid; the bacmecillinam salt of 6.beta.-iodopenicillanic acid, the penethamate salt of 6.beta.-bromopenicillanic acid; and the penethamate salt of 6.beta.-iodopenicillanic acid.
- 2. A salt according to claim 1, which is the pivmecillinam salt of 6.beta.-bromopenicillanic acid.
- 3. A salt according to claim 1, which is the pivmecillinam salt of 6.beta.-iodopenicillanic acid.
- 4. A salt according to claim 1, which is the bacmecillinam salt of 6.beta.-bromopenicillanic acid.
- 5. A salt according to claim 1, which is the bacmecillinam salt of 6.beta.-iodopenicillanic acid.
- 6. A salt according to claim 1, which is the penethamate salt of 6.beta.-bromopenicillanic acid.
- 7. A salt according to claim 1, which is the penethamate salt of 6.beta.-iodopenicillanic acid.
- 8. A pharmaceutical preparation in dosage unit form for enteral, parenteral, topical or intramammal treatment of human patients and animals suffering from infectious diseases, which comprises as the principal active component 0.025 g to 2.5 g of the sale of claim 1, in combination with one or more of a pharmaceutically acceptable, non-toxic carrier and/or auxiliary agent.
- 9. A pharmaceutical preparation in dosage unit form as claimed in claim 8, containing from 0.1 g to 1.0 g of said active ingredient.
- 10. A pharmaceutical preparation in dosage unit form as claimed in claim 8 in the form of tablets, pills, capsules, or suspensions.
- 11. A compounded pharmaceutical composition as claimed in claim 8 which also includes one or more of, as a further antibiotic, a penicillin, cephalosporin, amidino penicillanic acid, or easily hydrolyzable esters thereof, the ratio between the said principal active compound and said further antibiotic is between 1:10 and 10:1.
- 12. The compounded pharmaceutical composition of claim 11 wherein said ratio is between 1:3 and 3:1.
- 13. A method for treating a patient suffering from infectious diseases comprising administering to said patient a composition containing the salt of claim 1 in an amount of 1-425 mg/kg body weight of said patient/day, said composition optionally containing at least one .beta.-lactam antibiotic or a pro-drug thereof.
- 14. The pharmaceutical composition of claim 8, for veterinary use, which also contains as a .beta.-lactam antibiotic, at least penethamate or the hydroiodide thereof.
- 15. The pharmaceutical composition of claim 14 which also contains at least one antimicrobial agent used in the treatment of mastitis.
- 16. The compounded pharmaceutical composition of claim 11 for use in the treatment of bovine mastitis wherein said .beta.-lactam antibiotic is selected from the group consisting of benzyl-penicillin, ampicillin, amoxycillin, carbenicillin, cloxacillin, flucloxacillin, ticarcillin, nafcillin, dicloxacillin, oxacillin, methicillin, carfecillin, mecillinam, cephaloridine, cephalexin, cephacetrile, a mixture of ampicillin/cloxacillin, a mixture of amoxycillin/cloxacillin, a mixture of ampicillin/flucloxacillin, and a mixture of ampicillin/mecillinam.
- 17. The compounded pharmaceutical composition of claim 15 which also contains a further antibiotic selected from the group consisting of streptomycin, dihydrostreptomycin, neomycin, polymyxin B, polymyxin E, tetracyclines, framycetin, colimycin, gentamycin, erythromycin, canamycin, bacitracin, tyrothricin, sulfamerazine, sulfathioazole and sulfanilamide.
- 18. The compounded pharmaceutical composition of claim 16 which also contains one or more of a corticosteroid or pain-relieving agent.
- 19. The compounded pharmaceutical composition of claim 18 wherein the said .beta.-lactam antibiotic is penethamate or a salt thereof.
Priority Claims (4)
Number |
Date |
Country |
Kind |
7917665 |
May 1979 |
GBX |
|
7930819 |
Sep 1979 |
GBX |
|
7941252 |
Nov 1979 |
GBX |
|
8006681 |
Feb 1980 |
GBX |
|
Parent Case Info
This is a continuation of application Ser. No. 207,614, filed Nov. 17, 1980, now U.S. Pat. No. 4,446,184, which is a continuation-in-part of application Ser. No. 145,880, filed May 1, 1980, now U.S. Pat. No. 4,511,512.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4287181 |
Kellogg |
Sep 1981 |
|
4397783 |
Kellogg et al. |
Aug 1983 |
|
Non-Patent Literature Citations (1)
Entry |
Lymphology, vol. 12, No. 2, Jun. 1979. pp. 85-94. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
207614 |
Nov 1980 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
145880 |
May 1980 |
|